Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia

Ann Hematol. 2022 Nov;101(11):2563-2564. doi: 10.1007/s00277-022-04956-y. Epub 2022 Aug 17.

Authors

Marta Santaliestra¹, Francisca Ferrer-Marín², Alberto Alvarez-Larrán³; MPN Spanish Group (GEMFIN)

Affiliations

¹ Hematology Department, Hospital Universitari Mútua Terrassa, Terrassa, Spain. msantaliestra@mutuaterrassa.cat.
² Hematology and Medical Oncology Department, Centro Regional de Hemodonación, IMIB-Arrixaca, CIBERER, UCAM, Hospital Universitario Morales-Meseguer, Murcia, Spain.
³ Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

PMID: 35978180
DOI: 10.1007/s00277-022-04956-y

No abstract available

Publication types

Letter

MeSH terms

Hemorrhage / chemically induced
Humans
Platelet Aggregation Inhibitors / adverse effects
Quinazolines
Thrombocythemia, Essential* / complications
Thrombocythemia, Essential* / drug therapy
Thrombosis* / etiology
Thrombosis* / prevention & control

Substances

Platelet Aggregation Inhibitors
Quinazolines
anagrelide